Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in western Kenya
Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in western Kenya
复制标题
DOI：
10.1086/522632
复制
发表时间：
2007-11-01
影响因子：
6.4
通讯作者：
Nettey, Henry
中科院分区：
文献类型：
--
作者：
Green, Michael D.;van Eijk, Annemieke M.;Nettey, Henry
背景资料。磺胺多辛-乙胺嘧啶(SP)是妊娠期最常用的抗疟疾药物之一，但其在孕妇体内的药代动力学尚不清楚。感染艾滋病毒(HIV+)的妇女比未感染艾滋病毒(HIV-)的妇女需要更频繁的SP间歇预防性治疗剂量。我们调查了这是否反映了他们的免疫力受损或HIV相关的SP处置的改变。17名艾滋病毒孕妇和16名艾滋病毒阳性孕妇接受了1500毫克的磺胺多辛和75毫克的乙胺嘧啶。5名艾滋病毒携带者和6名艾滋病毒携带者产后2-3个月返回接受另一剂疫苗。比较磺胺多辛和乙胺嘧啶在两组间的药代动力学。在产前或产后妇女中，HIV状态并不影响曲线下面积(AUC(0->无穷大))或磺胺或乙胺嘧啶的半衰期，尽管分娩状态确实对磺胺多辛的药代动力学有显著影响。在产前妇女中，磺胺多辛的中位半衰期显著短于产后妇女(148比256小时；Pinfinity)，比产后妇女低40%(22,816比40,106 mg/mL/h，P
Background. Sulfadoxine-pyrimethamine (SP) is among the most commonly used antimalarial drugs during pregnancy, yet the pharmacokinetics of SP are unknown in pregnant women. HIV-infected (HIV+) women require more frequent doses of intermittent preventive therapy with SP than do HIV- uninfected (HIV-) women. We investigated whether this reflects their impaired immunity or an HIV- associated alteration in the disposition of SP.Methods. Seventeen pregnant HIV- women and 16 pregnant HIV+ women received a dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine. Five HIV- and 6 HIV+ postpartum women returned 2-3 months after delivery for another dose. The pharmacokinetics of sulfadoxine and pyrimethamine were compared between these groups.Results. HIV status did not affect the area under the curve (AUC(0 ->infinity)) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum women, although partum status did have a significant affect on sulfadoxine pharmacokinetics. Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; Pinfinity) was similar to 40% lower (22,816 vs 40,106 mg/ mL/ h, P